CBD outside hemp: no other known plant makes it

Hemp produces its cannabinoids in its trichomes, the small resin glands found mostly on the female flowers. The starting point is a single precursor, cannabigerolic acid (CBGA), which an enzyme called CBDA synthase converts into cannabidiolic acid (CBDA). Heat then removes a carboxyl group from CBDA to give CBD, a reaction called decarboxylation. The whole chain is set out on our page on CBG, the parent molecule of CBD.

The human body makes its own molecules that act on the CB1 and CB2 receptors. These endocannabinoids, anandamide and 2-AG, are built very differently from CBD. The receptor network is explained in our article on the endocannabinoid system.

The confusion comes from this shared target. A plant can contain a compound that reaches the same receptors and still hold no trace of CBD.

The plants that come up again and again in these discussions make either related molecules or compounds that act on the same receptors. Not one of them produces measurable CBD.

The South African everlasting is the strongest case. In 2023, a Weizmann Institute team published in Nature Plants an analysis of Helichrysum umbraculigerum, a member of the daisy family with no kinship to hemp. The plant holds up to 4.3% cannabigerolic acid, stored in the trichomes of its leaves, whereas hemp stores its own in the flowers. The authors show that its enzymes evolved independently of hemp's, a case of parallel evolution. According to the Weizmann Institute's release, six of its more than 40 cannabinoids match those of cannabis, CBG among them, while THC and CBD are absent.

The Siberian rhododendron, Rhododendron dauricum, produces daurichromenic acid in the glandular scales of its leaves. A 2017 study identified the enzyme that makes it. This enzyme works partly like the hemp synthases, on another substrate, grifolic acid, and its end product does not belong to the hemp cannabinoids.

Radula liverworts, small plants that look like moss, contain perrottetinene, a molecule shaped somewhat like THC. Researchers at the University of Bern showed in 2018 that it enters the mouse brain and acts through the CB1 receptor. Radula preparations are sold online as a "legal high". That has no connection with CBD, which produces no such effect.

Beta-caryophyllene, the compound behind the pepper claim, is a terpene found in large amounts in the essential oils of black pepper, oregano and cinnamon, as well as in hemp. A 2008 study described it as a selective ligand of the CB2 receptor, with an in vitro affinity of 155 nanomolar. A 2020 study that tested five terpenes found only a weak interaction with CB2. The findings conflict, and either way beta-caryophyllene does not convert into CBD. This research is covered in our article on beta-caryophyllene.

Hemp's pathway can be reproduced outside the plant. A Berkeley team reported in Nature in 2019 the complete biosynthesis of several cannabinoids in yeast, Saccharomyces cerevisiae, from a simple sugar, galactose. With the hemp genes and an enzyme no one had identified until then, the yeast made CBGA, THCA, CBDA and their short-chain equivalents, THCVA and CBDVA.

Synthetic chemistry makes CBD as well, with no living organism at all, and the latest opinion of the European Food Safety Authority concerns this kind of CBD. On 18 September 2026, EFSA assessed a CBD obtained by chemical synthesis, at least 98% pure, dissolved in medium-chain triglyceride oil and meant for food supplements. It judged it safe at up to 2 mg a day for adults over 25, outside pregnancy and breastfeeding. For people on medication, safety could not be established. The opinion authorises nothing: the European Commission decides with the member states whether a novel food enters the Union list.

A pure CBD molecule is chemically identical whether a flower, a yeast or a reactor produced it. The differences lie in possible impurities and in whatever accompanies the molecule. A plant extract carries other cannabinoids and terpenes, while a synthetic CBD or a 99% isolate holds almost none.

For hemp, the order of 30 December 2021 authorises Cannabis sativa L. varieties listed in the official catalogues with no more than 0.30% Δ⁹-THC, and sets the same ceiling for extracts and finished products. The Council of State decision of 29 December 2022 annulled the ban on selling flowers and leaves.

CBD meant to be swallowed falls under the EU novel food regulation, whether it comes from hemp or from a laboratory. The French agriculture ministry repeated this in a notice of 20 May 2026: foods containing CBD are illegal and must be taken off the market. The notice says cannabinoids "can be extracted by various processes or produced synthetically", so origin makes no difference. This framework is described in our overview of CBD regulation in 2026.

Modified molecules are a separate matter, and "synthetic CBD" should not be confused with a semi-synthetic cannabinoid. H4CBD, obtained by hydrogenating CBD, and HHC are distinct molecules. The ANSM, France's medicines agency, classified them as narcotics, with effect from 3 June 2024 for H4CBD. Our article on synthetic cannabinoids in CBD shows how to spot them.

The CBD level on its own tells you nothing about origin, since a 99% pure CBD can come from an extractor or from synthesis. Look at the rest of the profile:

Hemp flowers and resins are plant material by definition, so their certificate should show a full profile and Δ⁹-THC at 0.30% or less. Each line is explained in our guide to reading a certificate of analysis, and the laboratory page describes the testing methods. CBD flowers are hemp buds, and this full profile is what their certificate should show.